Vasopressin V1a receptor. Mediates vasoconstriction and platelet aggregation. Primary target for terlipressin (hepatorenal syndrome, septic shock). Gq-coupled.
CYFQNCPRG · 9 aa · @peptidemodel
| # | id | sequence | title | author | status | refs | metric | ♥ |
|---|---|---|---|---|---|---|---|---|
| 1 | pep-10872 | CYFQNCPRD | Desmopressin dDAVP | pe@peptidemodel | 2 | — | 0 | |
| 2 | pep-10514 | CYFQNCPR | (Arg8,des-Gly-NH29)-Vasopressin peptide | pe@peptidemodel | 6 | — | 0 | |
| 3 | pep-10513 | CYFQNCPKG | (Lys8)-Vasopressin peptide | pe@peptidemodel | 4 | — | 0 | |
| 4 | pep-10300 | CIQNCPG | AVPR2 ligand CHEMBL1817756 (7-mer) | pe@peptidemodel | 1 | — | 0 | |
| 5 | pep-10299 | CFINNCPG | AVPR2 ligand CHEMBL1817752 (8-mer) | pe@peptidemodel | 1 | — | 0 | |
| 6 | pep-10298 | CFIQNCPG | AVPR2 ligand CHEMBL1817703 (8-mer) | pe@peptidemodel | 1 | — | 0 | |
| 7 | pep-04423 | CYFQNCPRG | Vasopressin — Diabetes insipidus, enuresis | pe@peptidemodel | 3 | — | 0 |
No discussion threads yet.